本妥昔单抗-话题@MedSci

#本妥昔单抗#

7篇内容 | 1136人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2242040, encodeId=1b6522420404e, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a> <a href='/topic/show?id=f3d560938ab' target=_blank style='color:#2F92EE;'>#本妥昔单抗#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a>, objectTitle=Blood | 从化疗到免疫治疗：本妥昔单抗与纳武利尤单抗联合方案为霍奇金淋巴瘤患者带来新选择, objectType=article, longId=854952, objectId=53c6854952d3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241211/1733922161183_6145188.png, objectUrl=/article/show_article.do?id=53c6854952d3, replyNumber=0, likeNumber=10, createdTime=2024-12-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=53c6854952d3, moduleTitle=Blood | 从化疗到免疫治疗：本妥昔单抗与纳武利尤单抗联合方案为霍奇金淋巴瘤患者带来新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53c6854952d3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1619852, encodeId=71af161985252, content=<a href='/topic/show?id=f3d560938ab' target=_blank style='color:#2F92EE;'>#本妥昔单抗#</a>, objectTitle=Lancet Haemat：本妥昔单抗联合化疗治疗III/IV期经典霍奇金淋巴瘤的长期预后, objectType=article, longId=217739, objectId=0ff021e739a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ff021e739a7, replyNumber=0, likeNumber=106, createdTime=2021-09-28, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ff021e739a7, moduleTitle=Lancet Haemat：本妥昔单抗联合化疗治疗III/IV期经典霍奇金淋巴瘤的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ff021e739a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619851, encodeId=18bb1619851db, content=<a href='/topic/show?id=f3d560938ab' target=_blank style='color:#2F92EE;'>#本妥昔单抗#</a>, objectTitle=Blood：本妥昔单抗联合纳武单抗挽救治疗复发/难治性霍奇金淋巴瘤的长期预后, objectType=article, longId=215771, objectId=a6f3215e7119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6f3215e7119, replyNumber=0, likeNumber=71, createdTime=2021-08-17, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6f3215e7119, moduleTitle=Blood：本妥昔单抗联合纳武单抗挽救治疗复发/难治性霍奇金淋巴瘤的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6f3215e7119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619850, encodeId=81af161985023, content=<a href='/topic/show?id=f3d560938ab' target=_blank style='color:#2F92EE;'>#本妥昔单抗#</a>, objectTitle=J Clin Oncol：本妥昔单抗维多丁可显著减少高危型霍奇金淋巴瘤儿童患者的放疗剂量且不影响疗效, objectType=article, longId=210468, objectId=7cd7210468a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cd7210468a5, replyNumber=0, likeNumber=81, createdTime=2021-04-27, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cd7210468a5, moduleTitle=J Clin Oncol：本妥昔单抗维多丁可显著减少高危型霍奇金淋巴瘤儿童患者的放疗剂量且不影响疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cd7210468a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619849, encodeId=64b71619849be, content=<a href='/topic/show?id=f3d560938ab' target=_blank style='color:#2F92EE;'>#本妥昔单抗#</a>, objectTitle=Blood：本妥昔单抗联合纳武单抗治疗复发或难治性霍奇金淋巴瘤：3年研究结果, objectType=article, longId=210466, objectId=9b122104662e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b122104662e, replyNumber=0, likeNumber=105, createdTime=2021-04-27, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b122104662e, moduleTitle=Blood：本妥昔单抗联合纳武单抗治疗复发或难治性霍奇金淋巴瘤：3年研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b122104662e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619848, encodeId=e79516198482b, content=<a href='/topic/show?id=f3d560938ab' target=_blank style='color:#2F92EE;'>#本妥昔单抗#</a>, objectTitle=Blood：本妥昔单抗维多汀、阿霉素、长春碱联合达卡巴嗪治疗非大体积局限性霍奇金淋巴瘤的疗效和安全性, objectType=article, longId=168967, objectId=04af16896e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04af16896e43, replyNumber=0, likeNumber=100, createdTime=2019-06-24, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04af16896e43, moduleTitle=Blood：本妥昔单抗维多汀、阿霉素、长春碱联合达卡巴嗪治疗非大体积局限性霍奇金淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04af16896e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619847, encodeId=1931161984eb6, content=<a href='/topic/show?id=f3d560938ab' target=_blank style='color:#2F92EE;'>#本妥昔单抗#</a>, objectTitle=Blood：本妥昔单抗可显著提高高复发/进展风险的典型霍奇金淋巴瘤患者的无进展存活率, objectType=article, longId=150536, objectId=2c90150536e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c90150536e4, replyNumber=0, likeNumber=82, createdTime=2018-10-09, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c90150536e4, moduleTitle=Blood：本妥昔单抗可显著提高高复发/进展风险的典型霍奇金淋巴瘤患者的无进展存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c90150536e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619846, encodeId=fce4161984685, content=<a href='/topic/show?id=f3d560938ab' target=_blank style='color:#2F92EE;'>#本妥昔单抗#</a>, objectTitle=N Engl J Med：本妥昔单抗联合化疗晚期霍金淋巴瘤一线治疗重大突破, objectType=article, longId=128632, objectId=bc46128632c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc46128632c0, replyNumber=0, likeNumber=106, createdTime=2018-02-04, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc46128632c0, moduleTitle=N Engl J Med：本妥昔单抗联合化疗晚期霍金淋巴瘤一线治疗重大突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc46128632c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

本妥昔单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#霍奇金淋巴瘤# #本妥昔单抗# #纳武利尤单抗#

Blood | 从化疗到免疫治疗：本妥昔单抗与纳武利尤单抗联合方案为霍奇金淋巴瘤患者带来新选择

2024-12-12发表于上海

docwu2019 (审核中...)

前往app查看评论内容

#本妥昔单抗#

Lancet Haemat：本妥昔单抗联合化疗治疗III/IV期经典霍奇金淋巴瘤的长期预后

2021-09-28

docwu2019 (审核中...)

前往app查看评论内容

#本妥昔单抗#

Blood：本妥昔单抗联合纳武单抗挽救治疗复发/难治性霍奇金淋巴瘤的长期预后

2021-08-17

docwu2019 (审核中...)

前往app查看评论内容

#本妥昔单抗#

J Clin Oncol：本妥昔单抗维多丁可显著减少高危型霍奇金淋巴瘤儿童患者的放疗剂量且不影响疗效

2021-04-27

docwu2019 (审核中...)

前往app查看评论内容

#本妥昔单抗#

Blood：本妥昔单抗联合纳武单抗治疗复发或难治性霍奇金淋巴瘤：3年研究结果

2021-04-27

docwu2019 (审核中...)

前往app查看评论内容

#本妥昔单抗#

Blood：本妥昔单抗维多汀、阿霉素、长春碱联合达卡巴嗪治疗非大体积局限性霍奇金淋巴瘤的疗效和安全性

2019-06-24

docwu2019 (审核中...)

前往app查看评论内容

#本妥昔单抗#

Blood：本妥昔单抗可显著提高高复发/进展风险的典型霍奇金淋巴瘤患者的无进展存活率

2018-10-09

docwu2019 (审核中...)

前往app查看评论内容

#本妥昔单抗#

N Engl J Med：本妥昔单抗联合化疗晚期霍金淋巴瘤一线治疗重大突破

2018-02-04

科室
- - 订阅+
  - 更多科室
工具
服务